Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbralisib + Ublituximab in Naive FL/SLL
NCT03828448Phase 2Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- Jul 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of umbralisib in follicular lymphoma (FL), small lymphocytic lymphoma (SLL), sponsored by TG Therapeutics, Inc.. Started Jul 2019; status: terminated.
02
Drugs
umbralisib
03
Conditions
follicular lymphoma (FL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03828448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03828448.